dianas 9(1) > Maqueda-Zelaya etal

dianas | Vol 9 Num 1 | marzo 2020 | e202003c02

New synthetic strategies for treatment of the renal disease: synthesis of peptide nucleic acids.

F Maqueda-Zelaya^a, V Miguel, J L Aceña, S Lamas, J J Vaquero

Facultad de Farmacia. Universidad de Alcalá.

a. francisco.maqueda@uah.es

V Congreso de Señalización Celular, SECUAH 2020.
16-18 de marzo, 2020. Universidad de Alcalá. Alcalá de Henares, Madrid. España.

Keywords: peptide nucleic acids; chronic kidney disease; miRNA; SPS

Abstract

Chronic kidney disease (CKD) is defined as the persistence of abnormalities in urine or kidney function damage caused by the loss of functional nephrons and usually derives in transplant or hemodialysis. CKD is a first-magnitude clinical and socio-economic problem, being necessary to develop therapies that improve the life quality of patients and decrease the economic costs of this disease without treatment. One of the most promising biomarkers are microRNAs (miRNAs), which can also be used as therapeutic tools. In this work, a new approach for CKD treatment is shown. It is based on the inhibition of the protein translation by the coupling of peptide nucleic acids (PNAs) to their complementary mRNA, producing its degradation. PNAs are more stable alternatives to the use of miRNAs, can be synthetized by SPS and modified easily to improve the insertion, as well as location inside cell membranes by the linkage of appropriate cell-penetrating peptides (CPPs) and fluorophores.